Medline Industries, Inc., a leading global manufacturer and distributor of healthcare supplies, is headquartered in the United States. Founded in 1910, the company has established a strong presence in North America and beyond, serving hospitals, nursing homes, and other healthcare facilities. Medline is renowned for its extensive range of products, including surgical instruments, medical apparel, and infection prevention solutions, all designed to enhance patient care and operational efficiency. With a commitment to innovation, Medline has achieved significant milestones, such as expanding its product lines and investing in advanced manufacturing technologies. The company holds a prominent market position, recognised for its quality and reliability, making it a trusted partner in the healthcare industry. Medline's dedication to customer service and tailored solutions further distinguishes it in a competitive landscape.
How does Medline Industries's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medline Industries's score of 41 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Medline Industries reported total carbon emissions of approximately 7,278,301,000 kg CO2e globally. This figure includes 173,837,000 kg CO2e from Scope 1 emissions, 131,904,000 kg CO2e from Scope 2 emissions (primarily from purchased electricity), and a significant 6,972,560,000 kg CO2e from Scope 3 emissions, which encompass various categories such as purchased goods and services, business travel, and employee commuting. Medline has set ambitious climate commitments, aiming for near-zero emissions for both Scope 1 and Scope 2 by 2025. Specifically, they plan to reduce Scope 1 emissions by 30% from a 2023 baseline by 2030 and similarly target a 30% reduction in Scope 2 emissions within the same timeframe. Furthermore, the company is committed to achieving Net Zero emissions by 2050, with projections indicating a 42% reduction in total Scope 1 and Scope 2 emissions by 2030, alongside a 25% reduction in Scope 3 emissions, limited to specific sub-categories required by the NHS. These initiatives reflect Medline's dedication to addressing climate change and reducing its carbon footprint across all scopes of emissions.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2018 | 2019 | 2020 | 2021 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 45,201,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Scope 2 | 81,309,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Scope 3 | 90,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medline Industries is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.